In 2023, the operating profit of ToolGen amounted to a loss of around 42.3 billion South Korean won. The company has only seen net losses over the past decade. ToolGen is a South Korean biotech company based on CRISPR genome editing technology.
Net profit of ToolGen from 2013 to 2023
(in billion South Korean won)
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
DART. (March 29, 2024). Net profit of ToolGen from 2013 to 2023 (in billion South Korean won) [Graph]. In Statista. Retrieved November 21, 2024, from https://www.statista.com/statistics/1394288/toolgen-net-profit/
DART. "Net profit of ToolGen from 2013 to 2023 (in billion South Korean won)." Chart. March 29, 2024. Statista. Accessed November 21, 2024. https://www.statista.com/statistics/1394288/toolgen-net-profit/
DART. (2024). Net profit of ToolGen from 2013 to 2023 (in billion South Korean won). Statista. Statista Inc.. Accessed: November 21, 2024. https://www.statista.com/statistics/1394288/toolgen-net-profit/
DART. "Net Profit of Toolgen from 2013 to 2023 (in Billion South Korean Won)." Statista, Statista Inc., 29 Mar 2024, https://www.statista.com/statistics/1394288/toolgen-net-profit/
DART, Net profit of ToolGen from 2013 to 2023 (in billion South Korean won) Statista, https://www.statista.com/statistics/1394288/toolgen-net-profit/ (last visited November 21, 2024)
Net profit of ToolGen from 2013 to 2023 (in billion South Korean won) [Graph], DART, March 29, 2024. [Online]. Available: https://www.statista.com/statistics/1394288/toolgen-net-profit/